COMMENTARY

DOI: 10.4274/tjh.galenos.2022.2022.0247
Turk J Hematol 2022;39:204-205

Initial Rate of *BCR::ABL1* Decline for Response Prediction in Chronic Myeloid Leukemia

Kronik Myeloid Lösemi Tedavisine Yanıt Tahmininde Başlangıç *BCR::ABL1* Düşüş Hızı

Susan Branford[1,2,3]

[1]*Centre for Cancer Biology, SA Pathology, Adelaide, Australia*
[2]*University of South Australia, School of Pharmacy and Medical Science, Adelaide, Australia*
[3]*University of Adelaide, School of Medicine, Adelaide, Australia*

In this issue of the journal, Ceran et al. [1] confirm the importance of the initial rate of *BCR*::*ABL1* transcript decline as a prognostic indicator in a cohort of 40 first-line imatinib-treated patients. Patients with the most rapid reductions, which were assessed as the number of days over which *BCR*::*ABL1* halved after the commencement of imatinib, as well as the achievement of *BCR*::*ABL1* international scale ratios of ≤10%, were associated with molecular response and event-free survival. The reduction ratio of *BCR*::*ABL1*, measured as the ratio of the 3-month *BCR*::*ABL1* divided by the pre-imatinib level, also predicted responses.

A *BCR*::*ABL1* ratio of ≤10% measured at 3 months of tyrosine kinase inhibitor (TKI) therapy, termed an early molecular response, has consistently been demonstrated to be an important prognostic indicator [2,3,4]. Nevertheless, the European LeukemiaNet recommends intervention for treatment failure only if the ratio remains above 10% upon repeat analysis within 3 months [5]. The reason is that some patients with a ratio of >10% at 3 months will have a reduction to within the optimal response category without treatment intervention by 6 months. Studies have determined that such patients can be identified by the initial rate of *BCR*::*ABL1* reduction measured at 3 months [6,7]. Accurate identification of the patients who should switch therapy to reduce the risk of disease progression and death is critical. A single molecular test is considered insufficient to make such an important decision as a change of treatment. Imatinib is in general safe and the side effects are usually mild. The toxicity profile of second- and third-generation inhibitors is different to some degree. Several types of vascular events have been documented in patients treated with these more potent inhibitors and individual patient co-morbidities must be considered for treatment decisions [8]. Therefore, enhanced risk prediction of treatment failure is ideal.

The velocity of the initial response to TKI therapy can provide an early indication of whether a patient is responsive to targeted *BCR::ABL1* inhibition. Velocity can be measured by the change in *BCR*::*ABL1* ratio from baseline to 3 months of TKI therapy. The baseline *BCR*::*ABL1* ratios are variable and provide no prognostic information [6]. For example, a patient with a *BCR*::*ABL1* ratio at baseline of 10% that remains at 10% at 3 months has clearly not responded to TKI therapy and treatment failure is indicated. On the other hand, a patient with 100% *BCR*::*ABL1* at baseline who achieves a 1-log reduction of *BCR*::*ABL1* to 10% at 3 months has had a substantial response and treatment intervention is not warranted. Ceran et al. [1] measured the velocity of response as the ratio of the *BCR*::*ABL1* values from baseline to 3 months [6] and defined this ratio as the "reduction ratio". They determined that the optimal reduction ratio to predict a major molecular response was 0.04. However, the day of sample collection of the 3-month timepoint can vary from as early as 1.5 months after commencing TKI to as late as 4.5 months [9]. Therefore, the reduction ratio for a patient with a constant *BCR*::*ABL1* decline will change over time depending on the day of the 3-month collection. Perhaps a more accurate measure of the velocity of *BCR*::*ABL1* reduction is the *BCR*::*ABL1* halving time. This is the number of days over which *BCR*::*ABL1* halves on TKI therapy. Importantly, the halving time calculation takes into account the number of days between the baseline sample collection and the day of sample collection after commencing TKI therapy. The *BCR*::*ABL1* halving time should remain constant for patients

Address for Correspondence/Yazışma Adresi: Susan Branford, Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, Australia
E-mail : susan.branford@sa.gov.au ORCID: orcid.org/0000-0002-5095-7981

Received/Geliş tarihi: June 6, 2022
Accepted/Kabul tarihi: June 14, 2022

with an exponential decline, irrespective of the time lapse between baseline and the 3-month collection timepoint [7]. Ceran et al. [1] determined that the optimal *BCR*::*ABL1* halving time to predict a major molecular response was 24 days.

Their study of 40 patients was a small cohort; however, it provides important confirmatory data on the relevance of the velocity of *BCR*::*ABL1* transcript decline. Furthermore, the rate of decline measured from baseline to 3 months was more important for the prediction of a deep molecular response than the single *BCR*::*ABL1* ratio measured at 3 months. Achieving a deep molecular response is a critical milestone in molecular response for patients who aim to cease therapy in an attempt to achieve treatment-free remission. The study also contributed to the growing body of evidence that measuring *BCR*::*ABL1* transcript kinetics using a molecular method where *ABL1* is the control gene is possible [10,11,12,13]. It was suggested that limitations related to the use of *ABL1* for real-time quantitative PCR analysis would preclude a reliable assessment of the kinetics of response since most methods that amplify *ABL1* also amplify *BCR*::*ABL1* [6].

In conclusion, measuring *BCR*::*ABL1* ratios at early timepoints after commencing TKI therapy remains an important prognostic indicator. Importantly, the rate of initial *BCR*::*ABL1* decline from the baseline measurement is a better predictor than a single measurement at 3 months for some patients.

References

1. Ceran F, Akıncı S, Uçar MA, Korkmaz G, Gündüz M, Çavdarlı B, Bakanay ŞM, Falay M, Dağdaş S, Dilek İ, Özet G. Predictive factors for molecular response in chronic myeloid leukemia: reduction ratio and halving time of *BCR-ABL1* IS transcript levels. Turk J Hematol 2022;39:196-203.
2. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Assessment of *BCR-ABL1* transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232-238.
3. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Sausele S, Hochhaus A. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096-2102.
4. Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 2012;30:4323-4329.
5. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saussele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966-984.
6. Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hanel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Muller MC; SAKK and the German CML Study Group. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014;28:1988-1992.
7. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP. Prognosis for patients with CML and >10% *BCR-ABL1* after 3 months of imatinib depends on the rate of *BCR-ABL1* decline. Blood 2014;124:511-518.
8. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015;125:901-906.
9. Pfirrmann M, Hochhaus A, Lauseker M, Sausele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011;25:1433-1438.
10. Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F. Major molecular response achievement in CML patients can be predicted by *BCR-ABL1/ABL1* or *BCR-ABL1/GUS* ratio at an earlier time point of follow-up than currently recommended. PLoS One 2014;9:e106250.
11. Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P. *BCR-ABL1* doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors. Front Oncol 2019;9:764.
12. Karpurmath SV, Seshachalam A, Selvaraj K, Rajamani P, Satish K, Reddy N, Malipatil B, Sirigeri R, Prasad K, Reddy K, Danthala M, Udupa KS, Nandennavar M, Murugesan J, Patil CN, Parameshwaran A, Jacob RK, Kalashetty M, Rathnam K, Ganapathy R. Halving time of *BCR-ABL1* in chronic myeloid leukemia, is it better than day-90 value – multicenter study from south India. Clin Lymphoma Myeloma Leuk 2020;20:e205-e211.
13. Stuckey R, Casado LF, Colomer D, Gomez-Casares MT, Casas L, Garcia-Gutierrez V, Sastre JL, Ramirez-Payer A, Vall-Llovera F, Goni MA, Xicoy B, Godoy AC, Nunez J, Mora I, Vallansot R, Lopez-Lorenzo JL, Palomera L, Conesa V, Noya MS, Sanchez-Guijo F, Pena A, Bautista G, Steegmann JL. Early prediction of subsequent molecular response to nilotinib in patients with chronic myeloid leukemia: comparison of the quantification of BCR-ABL1 ratios using *ABL1* or *GUSB* control genes. J Mol Diagn 2020;22:1217-1224.